MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors
G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck · 2026
Read MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors by G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13320502.txt.
Description
G. Mammone and colleagues weigh a jaw bone risk in a 2026 review of patient records. Some cancer drugs that slow bone breakdown can, in rare cases, kill jaw bone tissue. The question was whether adding blood vessel growth blockers, called VEGFR-TKIs, raises that risk further.
Records covered 233 people on both drug types and 986 people on bone drugs alone. Raw time to jaw harm looked shorter with both drugs, yet after checks for age, sex, smoking, and drug type the added drugs alone did not predict harm. Denosumab use and active smoking did. Among people on one bone drug class, the vessel blockers were tied to earlier harm, a split that needs care in clinic planning.
Catalog record
| CREATOR | G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51065 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |